Business article - January 17, 2024
How to pitch to life science VCs
Nordic life science companies are generally of good quality, but can often be better at pitching compared to US-based companies and entrepreneurs. Effective pitching is a skill, and is centered on good storytelling to get an investor’s full attention and buy-in. Since I work for the life science VC, HealthCap, I thought I would share […]
Business article - January 10, 2024
A Biotech Powerhouse
For the past decade Danish Genmab has experienced rapid growth and become an integrated biotech innovation powerhouse with a strong international footprint. NLS asked Birgitte Stephensen, Executive Vice President, Chief Legal Officer & Site Lead at Genmab in the Valby district of Copenhagen, about her company’s journey, its growth and its future plans. Genmab was […]
Business article - December 20, 2023
Quantum computing – Solving the most complex life science issues
The power of quantum computing holds great promise for the life science industry, not least speeding up and reducing costs within drug discovery. McKinsey & Company describes quantum computing like this in one of their Insight articles (What is quantum computing? 2023): “Classic computing is built on bits while quantum computing is built on quantum […]
Business article - December 18, 2023
Norges forskningsråd awards millions to cancer companies
Norges forskningsråd awards more than NOK 808 million to innovation projects in the industry. Several of these companies are also a part of Oslo Cancer Cluster Incubator. It is indeed a validation of the quality of the ecosystem.” “This is foremost fantastic news to hard working and risk-taking individuals in the companies, congratulations! It is […]
Business article - December 13, 2023
Increasing the precision of cancer medicine
Norway’s strengths in immunology and cancer R&D have probably not gone unnoticed by anyone within the Nordic life science industry, and perhaps also beyond. Next in a line of promising Norwegian spin-outs is Oncosyne – with a quest to become a leading provider of cell-based cancer diagnostics. Cancer is the second leading cause of death […]
Business article - December 6, 2023
Hansa Biopharma plans restructuring
The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately SEK 75-85 million in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions. While we firmly believe this initiative is a necessary action to help us deliver on our mission, it […]
